wire - news in brief
« BACK
Health - Pharmacology - 31.03.2021
Health - Pharmacology - 30.03.2021
Health - Pharmacology - 30.03.2021
Pharmacology - Health - 30.03.2021
Health - Pharmacology - 25.03.2021
Pharmacology - Health - 24.03.2021 
Clinical Trial of Multi Drug-Resistant TB Treatment Ends Enrolment Early, Offering Hope for TB Patients
A trial aiming to find a better treatment for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early after its independent data safety and monitoring board indicated that the regimen being studied is superior to current care, and that more patient data was extremely unlikely to change the trial's outcome.
Pharmacology - Health - 23.03.2021
Pharmacology - 23.03.2021
Health - Pharmacology - 18.03.2021 
Learning from the dead to help the living
The lungs are the primary, but not the only target of Covid-19. Early in the pandemic, Basel researchers were among the first to venture to perform autopsies on deceased Covid-19 patients, making important contributions to our understanding of the new infectious disease. Professor Alexandar Tzankov of the University of Basel is leading a research project highlighting the effects of the virus on the body's tissues and organs.
Pharmacology - Health - 15.03.2021
Pharmacology - Health - 11.03.2021
Health - Pharmacology - 11.03.2021
Pharmacology - Health - 09.03.2021
Pharmacology - 05.03.2021
Pharmacology - Health - 04.03.2021
Pharmacology - Environment - 03.03.2021
Health - Pharmacology - 26.02.2021
Pharmacology - Health - 26.02.2021
Pharmacology - Health - 26.02.2021
Health - Pharmacology - 26.02.2021
Pharmacology - 25.02.2021
Health - Pharmacology - 25.02.2021
Health - Pharmacology - 17.02.2021
Health - Pharmacology - 16.02.2021
Pharmacology - Health - 16.02.2021
Pharmacology - Health - 12.02.2021
Pharmacology - Economics / Business - 11.02.2021
Health - Pharmacology - 10.02.2021 
A very aggressive cancer defeated in three months
A team from the University of Geneva and HUG managed to save a woman whose aggressive cancer left her with only five months to live.
Health - Pharmacology - 08.02.2021
Pharmacology - Health - 08.02.2021
Pharmacology - 03.02.2021
Pharmacology - Health - 29.01.2021
Health - Pharmacology - 29.01.2021
Pharmacology - Health - 29.01.2021
Health - Pharmacology - 28.01.2021
Pharmacology - Health - 26.01.2021
Health - Pharmacology - 25.01.2021 
A treatment for every kind of cancer
Researchers from the University of Basel have identified cells in the immune system that are able to attack a wide range of cancer cells.
Health - Pharmacology - 25.01.2021
Health - Pharmacology - 19.01.2021
Pharmacology - Health - 14.01.2021
Health - Pharmacology - 12.01.2021
Pharmacology - Health - 12.01.2021
Health - Pharmacology - 11.01.2021
Pharmacology - Health - 11.01.2021
Health - Pharmacology - 05.01.2021
Pharmacology - Health - 19.12.2020
Health - Pharmacology - 19.12.2020
Life Sciences - Pharmacology - 18.12.2020 
A weather station for epileptic seizure
The unpredictability of epileptic seizures is a severe handicap for patients.
Pharmacology - Health - 18.12.2020
Health - Pharmacology - 17.12.2020
Pharmacology
Results 1 - 50 of 1562.
Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging
The Elecsys EBV panel accurately identifies the EBV infection stage from a single blood sample, which means less confirmatory testing and, potentially, faster diagnosis for patients Clear and quick d
The Elecsys EBV panel accurately identifies the EBV infection stage from a single blood sample, which means less confirmatory testing and, potentially, faster diagnosis for patients Clear and quick d
A trial aiming to find a better treatment for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early after its independent data safety and monitoring board indicated that the regimen being studied is superior to current care, and that more patient data was extremely unlikely to change the trial's outcome.
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive
Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive
The lungs are the primary, but not the only target of Covid-19. Early in the pandemic, Basel researchers were among the first to venture to perform autopsies on deceased Covid-19 patients, making important contributions to our understanding of the new infectious disease. Professor Alexandar Tzankov of the University of Basel is leading a research project highlighting the effects of the virus on the body's tissues and organs.
New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious, tr
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious, tr
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
CHMP has completed a review of available data for investigational antibody cocktail casirivimab and imdevimab (REGN-COV2) to be considered for the treatment of confirmed COVID-19 CHMP scientific op
CHMP has completed a review of available data for investigational antibody cocktail casirivimab and imdevimab (REGN-COV2) to be considered for the treatment of confirmed COVID-19 CHMP scientific op
Novartis Cosentyx gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis
Cosentyx (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations of PsA in a dedicated trial 1,2 ,3 .
Cosentyx (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations of PsA in a dedicated trial 1,2 ,3 .
Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine
FIREFISH Part 1 data show treatment with Evrysdi at 12 months helped 90% of these infants survive without permanent ventilation and 33% sit without support, a key motor milestone not normally seen in
FIREFISH Part 1 data show treatment with Evrysdi at 12 months helped 90% of these infants survive without permanent ventilation and 33% sit without support, a key motor milestone not normally seen in
Novartis Entresto granted expanded indication in chronic heart failure by FDA
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFr
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFr
A team from the University of Geneva and HUG managed to save a woman whose aggressive cancer left her with only five months to live.
Novartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemia
Designation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an investigat
Designation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an investigat
Novartis receives positive CHMP opinion for Kesimpta * (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis
Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS 1 CHMP opinion is base
Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS 1 CHMP opinion is base
Researchers from the University of Basel have identified cells in the immune system that are able to attack a wide range of cancer cells.
A new ’double’ antibody that protects against Covid-19 and its variations discovered in Ticino
The Institute for Research in Biomedicine (IRB, affiliated to USI Universitą della Svizzera italiana, has developed a second-generation 'double antibody' that protects from SARS-CoV-2, the virus causing COVID-19, and all its tested variants.
The Institute for Research in Biomedicine (IRB, affiliated to USI Universitą della Svizzera italiana, has developed a second-generation 'double antibody' that protects from SARS-CoV-2, the virus causing COVID-19, and all its tested variants.
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1 Currently th
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1 Currently th
Second COVID-19 vaccine approved for Switzerland
On 12 January 2021 Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, approved the second COVID-19 vaccination for the Swiss market.
On 12 January 2021 Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, approved the second COVID-19 vaccination for the Swiss market.
New Ebolavirus treatment sees the light thanks to basic research performed in Ticino
While populations around the world are being vaccinated against SARS-CoV-2, the U.S. Food and Drug Administration has announced the approval of a treament against another well-known virus, much less widespread but extremely lethal: Ebola.
While populations around the world are being vaccinated against SARS-CoV-2, the U.S. Food and Drug Administration has announced the approval of a treament against another well-known virus, much less widespread but extremely lethal: Ebola.
Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland
Vaccine from Pfizer/BioNTech authorised in the rolling review procedure after close scrutiny of the risks and benefits Swissmedic has authorised the vaccine from Pfizer/BioNTech.
Vaccine from Pfizer/BioNTech authorised in the rolling review procedure after close scrutiny of the risks and benefits Swissmedic has authorised the vaccine from Pfizer/BioNTech.
The unpredictability of epileptic seizures is a severe handicap for patients.
